Law360, New York (December 16, 2011, 3:09 PM ET) -- Settlements of Hatch-Waxman litigation between branded and generic pharmaceutical companies that include a “reverse payment” by the branded firm to the generic have been the subject of significant antitrust litigation over the past several years.
Courts have not tended to use either a “per se” or “rule of reason” analysis, instead adopting a “scope of the patent” test to review such settlements.
This approach takes into account the particularized regulatory and patent enforcement framework under the Hatch-Waxman Act that governs both the relationship between branded and...
Scrutinizing Reverse-Payment Settlements
To view the full article, take a free trial now.
